We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
+7.75%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$3.7B
AUM Growth
+$80.1M
Cap. Flow
-$18.8M
Cap. Flow %
-0.51%
Top 10 Hldgs %
34.9%
Holding
147
New
53
Increased
24
Reduced
24
Closed
35

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$134M
2
LLY icon
Eli Lilly
LLY
+$114M
3
HOLX
Hologic
HOLX
+$80.8M
4
NEO icon
NeoGenomics
NEO
+$60.6M
5
BIIB icon
Biogen
BIIB
+$55.7M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$182M
2
ISRG icon
Intuitive Surgical
ISRG
+$103M
3
ABBV icon
AbbVie
ABBV
+$66.8M
4
MDT icon
Medtronic
MDT
+$61.4M
5
BHC icon
Bausch Health
BHC
+$60M

Sector Composition

Rank Sector Weight
1 Healthcare 97.32%
2 Technology 1.61%
3 Financials 0.8%
4 Consumer Discretionary 0.14%
5 Miscellaneous 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRTX icon
1
Vertex Pharmaceuticals
VRTX
$137B
$192M 5.18%
950,000
+639,100
+206% +$134M
ABBV icon
2
AbbVie
ABBV
$451B
$167M 4.52%
1,484,400
-592,800
-29% -$66.8M
ARVN icon
3
Arvinas
ARVN
$600M
$143M 3.86%
1,854,000
+93,700
+5% +$6.5M
LLY icon
4
Eli Lilly
LLY
$1.05T
$130M 3.51%
+565,500
New +$114M
MRVI icon
5
Maravai LifeSciences
MRVI
$1.14B
$124M 3.34%
2,963,545
+202,000
+7% +$7.83M
MRTX
6
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$122M 3.29%
753,000
+277,300
+58% +$44.5M
ZNTL icon
7
Zentalis Pharmaceuticals
ZNTL
$360M
$115M 3.11%
2,160,000
+896,700
+71% +$48M
AVTR icon
8
Avantor
AVTR
$9.86B
$113M 3.05%
3,180,000
-1,805,100
-36% -$58.4M
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
$101M 2.73%
640,000
+62,100
+11% +$9.23M
BHVN
10
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$85.7M 2.32%
882,500
-167,300
-16% -$13.6M
HOLX
11
DELISTED
Hologic
HOLX
$80.7M 2.18%
+1,208,800
New +$80.8M
SNDX icon
12
Syndax Pharmaceuticals
SNDX
$1.74B
$79.2M 2.14%
4,615,000
+769,000
+20% +$14.1M
EPIX
13
DELISTED
ESSA Pharma
EPIX
$78.6M 2.12%
2,750,000
-90,000
-3% -$2.62M
EXAS
14
DELISTED
Exact Sciences
EXAS
$73.3M 1.98%
590,000
-8,000
-1% -$955K
MDT icon
15
Medtronic
MDT
$117B
$66.4M 1.79%
535,000
-489,200
-48% -$61.4M
NBIX icon
16
Neurocrine Biosciences
NBIX
$15.7B
$66.3M 1.79%
681,000
+159,600
+31% +$15.3M
NUVB icon
17
Nuvation Bio
NUVB
$2.34B
$64.9M 1.75%
6,966,376
-555,565
-7% -$6.34M
ARNA
18
DELISTED
Arena Pharmaceuticals Inc
ARNA
$64.3M 1.74%
943,000
+44,450
+5% +$2.9M
BIIB icon
19
Biogen
BIIB
$32.3B
$63.7M 1.72%
+183,900
New +$55.7M
NEO icon
20
NeoGenomics
NEO
$2.32B
$61.7M 1.67%
+1,367,000
New +$60.6M
NTLA icon
21
Intellia Therapeutics
NTLA
$1.8B
$61.5M 1.66%
+380,000
New +$29.6M
NBP
22
NovaBridge Biosciences American Depositary Shares
NBP
$213M
$61.2M 1.65%
729,000
-600,000
-45% -$39.6M
CTLT
23
DELISTED
CATALENT, INC.
CTLT
$58.4M 1.58%
540,000
-20,000
-4% -$2.14M
STTK icon
24
Shattuck Labs
STTK
$707M
$56.2M 1.52%
1,940,200
+609,815
+46% +$17.8M
CNC icon
25
Centene
CNC
$32B
$54.8M 1.48%
+751,200
New +$51.5M
1
2 3 4 5

Similar funds

DCM
Davidson Capital Management Corpus Christi, Texas $624M AUM 29.17% 1-Year Est. Return
SIG
Spinnaker Investment Group Newport Beach, California $624M AUM 17.54% 1-Year Est. Return
PFA
Pettinga Financial Advisors Evansville, Indiana $624M AUM 24.87% 1-Year Est. Return
ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
CWM
Chemistry Wealth Management New York $625M AUM 19.32% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return

Avidity Partners Management's Q2 2021 Portfolio in Review

As of Q2 2021, Avidity Partners Management held 147 positions worth $3.7B, up 2.2% from $3.62B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Avidity Partners Management's Q2 2021 filing shows 53 new, 24 increased, 24 reduced and 35 closed positions. Its largest new stake was Eli Lilly: 565,500 shares worth $130M. The largest sale was AstraZeneca, an estimated $182M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Technology and Financials.

  • Avidity Partners Management's largest Q2 2021 buy was Eli Lilly: 565,500 shares worth $130M.
  • Avidity Partners Management added most to Vertex Pharmaceuticals in Q2 2021, an estimated $134M increase.
  • Avidity Partners Management's biggest Q2 2021 reduction was AbbVie, cutting an estimated $66.8M.
  • Avidity Partners Management fully exited AstraZeneca in Q2 2021, selling an estimated $182M.
  • Avidity Partners Management's ten largest holdings make up 35% of its $3.7B portfolio in Q2 2021.
  • Avidity Partners Management opened 53 new positions and closed 35 in Q2 2021.
  • Avidity Partners Management's portfolio value rose 2.2% quarter-over-quarter to $3.7B.

Based on Avidity Partners Management's 13F filing for Q2 2021, filed 16 Aug 2021.